Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Add as a preferred source on Google
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
